Argentina Menopause Drugs Market – Industry Trends and Forecast to 2029

Market Analysis and Insights: Argentina Menopause Drugs Market  

Argentina menopause drugs market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.6% in the forecast period of 2022 to 2029 and is expected to reach USD 50.80 million by 2029 from USD 35.65 million in 2021. The rise in ageing population among women in Argentina and ongoing research and development for hormonal and non-hormonal therapy medications to cure menopause are likely to be the major drivers which propel the market growth in the forecast period.

The term menopause means a specific time period, for 12 months after a woman's last period. The years leading up to the point, when women may have changes in the menstrual cycles. During menopause, a woman's body makes less of the hormones estrogen and progesterone. The lower hormone levels, lead to onset of menopause symptoms such as hot flashes, vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression and weight gain.

Some women choose to treat their menopause symptoms with hormonal and non-hormonal therapies. The hormonal therapy medications are estrogen, progesterone, a cocktail of estrogen with progesterone drugs and medroxyprogesterone acetate. The progestin-only medicines are taken with estrogen-only medicines, to lower the chance of getting endometrial cancer in women who still have their uterus.

Argentina has one of the largest populations of the elderly people in Latin America. The ageing population in Argentina are due to rise in fertility and mortality rates. The shift causes an increase in demand for long-term care for older people, particularly those requiring help with activities of daily living. Menopause had started in women aged 47 years in Argentina. In 2020, the data by the American Development Bank stated that 15.7% of women in Argentina were ageing.

The hormone therapy (HT) is one of the initiatives by the government for treatment of menopausal symptoms. The government initiatives refer to statement or programs which are necessitated to solve the problem. The government raises awareness or delivers initiatives for better health, reduced cost and safety for the treatment of menopause symptoms.

For instance,

• The Women’s Health Initiative (WHI) hormone therapy (HT) is a government organization in Argentina, which determines the benefits and risks of HT taken for chronic disease prevention by predominantly healthy postmenopausal women

The driving factors responsible for the growth of the Argentina menopause drugs market the increased research and development, rise in ageing population among women, rise in government organizations and funding in Argentina, reimbursement and rise in product approvals. However, the factors that are expected to restrain the market are the rise in the cost of the menopause drugs, rise in product recall. Lack of awareness about knowledge of menopause in Argentina and complexity in menopause.

• On the other hand, strategic initiatives by market players, rise in healthcare expenditure and use of dietary supplements may act as an opportunity for the growth of the Argentina menopause drugs market. The need for skilled expertise and the regulatory approval may create challenges for the Argentina menopause drugs market. There are recent developments related to the Argentina menopause drugs market.

The Argentina menopause drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.   

Argentina Menopause Drugs Market Scope and Market Size

The Argentina menopause drugs market is categorized into seven segments: stages, type, menopause symptoms, dosage forms, route of administration, end user and distribution channel.

• On the basis of stages, the Argentina menopause drugs market is segmented into postmenopause, perimenopause, and menopause. In 2022, the postmenopause segment is expected to dominate the Argentina menopause drugs market due to high therapeutic potential of the selected drug.
• On the basis of type, the Argentina menopause drugs market is segmented into non-hormonal therapy and hormonal therapy. In 2022, the non- hormonal therapy segment is expected to dominate the Argentina menopause drugs market due to ensure the drug target has potential therapeutic benefit, ease of administration of supplements and  increased awareness of post-menopausal issues among women.
• On the basis of menopause symptoms, the Argentina menopause drugs market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression, weight gain and others. In 2022, the vasomotor segment is expected to dominate the Argentina menopause drugs market due to the increased demand for treatment of hot flashes and vaginal dryness, which occurs due to vasomotor symptoms, market players investing in research and development (R&D) and rise in disposable income.
• On the basis of dosage form, the Argentina menopause drugs market is segmented into tablet, cream, patch/film, rings, gel, injection shot, spray, and others. In 2022, the tablets segment is expected to dominate the Argentina menopause drugs market, owing to the increased preference of oral administration for treatment of hot flashes and dyspareunia, by middle aged women in Argentina, rise in consciousness about the onset of menopausal symptoms and growth in retail of tablets.
• On the basis of route of administration, the Argentina menopause drugs market is segmented into oral, parenteral, transdermal, vaginal, and others. In 2022, the oral segment is expected to dominate the Argentina menopause drugs market, as most of the drugs offered by the companies and highly used by consumers are oral therefore this segment is predicted to dominate the market.
• On the basis of end user, the Argentina menopause drugs market is segmented into hospitals, clinics, home healthcare, and others. In 2022, the hospitals segment is expected to dominate the Argentina menopause drugs market due to rise in research and development of exosomes and support from government in funding in Argentina for the development of menopause drugs and correct prescription and guidance delivered by gynaecologists for correct use of hormonal and non-hormonal therapy are predicted to dominate the market.
• On the basis of distribution channel, the Argentina menopause drugs market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2022, the hospital pharmacy segment is expected to dominate the Argentina menopause drugs market due increased interaction with certified prescribers and health professionals for use of anti-depressant and guaranteed payment, are predicted to dominate the market.

Argentina Menopause Drugs Market Country Level Analysis

The Argentina menopause drugs market is analysed and market size information is provided by country, stages, type, menopause symptoms, dosage forms, route of administration, end user and distribution channel.

The country covered in the Argentina menopause drugs market report is Argentina. In 2022, Argentina is dominating the market, due to rise in research and development for menopause drugs in the pharmaceutical companies in Argentina and rise in product approvals from National Administration of Drugs, Foods and Medical Devices (ANMAT). 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential of the Argentina Menopause Drugs in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Argentina Menopause Drugs market

Argentina menopause drugs market also provides you with detailed market analysis for every country growth in particular industry with wound debridement device sales, impact of advancement in the Argentina menopause drugs and changes in regulatory scenarios with their support for the Argentina menopause drugs market. The data is available for historic period 2011 to 2020.

Competitive Landscape and Argentina Menopause Drugs Market Share Analysis

Argentina menopause drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Argentina menopause drugs market.

The major companies providing the Argentina menopause drugs are Laboratorios Bagó S.A., Química Montpellier SA, GADOR S.A., Laboratorio Elea Phoenix S.A., ROEMMERS SAICF, ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A., and Abbott. Laboratorios Bernabó, GlaxoSmithKline plc, TEMIS LOSTALO, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Allergan, Teva Pharmaceutical Industries Ltd., and Bayer AG among others.

The strategic initiatives by market players along with research and development for hormonal and non-hormonal therapy for Argentina menopause drugs is expected to increase the net revenue and sales of the menopause drugs.

For instance,

• In October 2020, Pfizer Inc. announced that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis . This helped the company to grow its product portfolio.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the Argentina menopause drugs market which also provides the benefit for organisation to improve their offering for treatment products.

SKU-67442